Matching articles for "Erzofri"
In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)
The FDA has approved Erzofri (Luye), an extended-release injectable formulation of the second-generation antipsychotic drug paliperidone palmitate, for treatment of schizophrenia and schizoaffective disorder…
Med Lett Drugs Ther. 2024 Oct 14; 66(1713):e171 doi:10.58347/tml.2024.1713j
The FDA has approved Erzofri (Luye), an extended-release injectable formulation of the second-generation antipsychotic drug paliperidone palmitate, for treatment of schizophrenia and schizoaffective disorder in adults. It is the second once-monthly formulation of paliperidone palmitate to be approved in the US for these indications; Invega Sustenna was the first. Longer-acting injectable formulations of paliperidone palmitate are also available (see Table 1).
